Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics, Inc. - Common Stock (NQ:KRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results. 
Via Benzinga
S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?
The S&P 500 and Nasdaq 100 indices are on the verge of achieving an impressive eight consecutive weeks of gains following a more significant decline than expected in the Federal Reserve’s favored... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Karuna Therapeutics Inc. (NASDAQ: KRTX) is a Leading Gainer in 12/22 Morning Trading
Via Investor Brand Network
Where Karuna Therapeutics Stands With Analysts
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review
Despite a Wednesday tumble, the major indexes are right at 2023 highs. 
Via Investor's Business Daily
Gold Moves Higher; US Consumer Sentiment Improves In December
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Friday. The Dow traded up 0.16% to 37,465.58 while the NASDAQ rose 0.28% to 15,005.25. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Latest Analyst Ratings for Karuna Therapeutics
Via Benzinga
Analyst Expectations for Karuna Therapeutics's Future
Via Benzinga
With Karuna Therapeutics $14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst
Earlier Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 bill 
Via Benzinga
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition... 
Via Benzinga
Topics Stocks
Exposures US Equities
Health Care Company Bristol-Myers Squibb Announces Merger With Karuna Therapeutics
Via Benzinga
Dow Rises 50 Points; Fed's Preferred Inflation Gauge Cools In November
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 50 points on Friday. Following the market opening Friday, the Dow traded up 0.14% to 37,458.12 while the NASDAQ rose... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Bristol Myers Squibb Scoops Up Schizophrenia Player Karuna Therapeutics In Massive $14B Deal
On Friday, Bristol Myers Squibb & Co (NYSE: BMY) agreed to acquire Karuna Therapeutics Inc (NASDAQ: KRTX) for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion n 
Via Benzinga
Premarket Moves: Nike Dips 11%, Karuna Therapeutics Soars 48%
Friday has seen several stocks make notable moves ahead of the market opening, with Nike (NKE​​​​​​​) and Karuna Therapeutics (KRTX) capturing the most attention. 
Via Talk Markets
Karuna Stock Soars On Bristol Myers' $14 Billion Takeover
Karuna is working on treatments for schizophrenia and Alzheimer's disease psychosis. 
Via Investor's Business Daily
KRTX STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Karuna Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
From PureTech Health plc
Via Business Wire
Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Says Its Antipsychotic Candidate Shows Favorable Cardiovascular Safety Profile In Schizophrenia Patients
Karuna Therapeutics Inc (NASDAQ: KRTX) released results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT (xanomeline-trospium) on 24-hour ambulatory blood... 
Via Benzinga
Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Announce Third Quarter 2023 Financial Results and Provide General Business Update on Thursday, November 2, 2023
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 36th European College of Neuropsychopharmacology (ECNP) Congress
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Takes A Big Step In Schizophrenia Treatment. Shares Jump Higher.
Karuna Therapeutics says it could have the first new mechanism for schizophrenia treatment in decades. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.